CX3CL1 and rheumatoid arthritis: E6011, a novel cell trafficking inhibitor targeting the human fractalkine-CX3CR1 interaction, demonstrated significant therapeutic effects at week 24, although it did not achieve the primary endpoint at week 12 in RA [45, 46].